, 2009). Intracellular bioactivity in such scenarios can, however, be improved by modifying the cellular environment. For example, alkalinization of endosomal pH by agents like chloroquine can decrease sequestration of drug and improve their cytotoxicity (Lee & Tannock, 2006). Further, drugs that are environmentally sensitive in their action can be combined with other therapies to enhance their efficacy. For example, macrolide antibiotic
Bafilomycin A1 when used alone is not effective against intracellular Diplorickettsia massiliensis infection (Subramanian et al., 2011). But, when combined with chlaramphenicol, they are active at lower concentrations. Similarly, the incorporation of streptomycin and doxycycline into macromolecular polymeric complexes simultaneously is more Rucaparib ic50 effective in treating murine brucellosis relative to free drugs (Seleem et al., 2009a ,b). Thus, environmentally sensitive therapies may be an elegant treatment approach for improving the intracellular bioactivity of drugs in many clinical situations. While the goals of improving antimicrobial levels in the infected cells cannot be overstated, an effective interventional strategy directly against the bacteria
also needs to be pursued simultaneously. Examples of such an approach includes blocking access to micronutrients like iron or targeting of specific bacterial genes involved in intracellular bacterial
selleck inhibitor growth. To obtain iron, a bacterium produces strong iron chelators called siderophores (Jain et al., 2011). Deletion of genes (for example, entF) responsible for siderophore production has been shown to affect bacterial multiplication in iron minimal media. Therefore, incorporation of micronutrient chelators in a drug delivery system is highly recommended. Similarly, modulations of bacterial genes by synthetic oligonucleotide has been shown to inhibit intracellular bacterial growth (Mitev et al., 2009). For example, phosphorodiamidate morpholino oligomers (PMO) are high molecular weights antisense oligomer. But, owing to their Pregnenolone polarity, they are poorly cell membrane permeable. Conjugation of these oligomers to cell-penetrating peptide can result in better intracellular accumulation and clearance of Salmonella from macrophage cells. Most importantly, these conjugated oligomers can enter macrophages and even enter Salmonella-containing vacuoles. The major drawbacks of PMO are their lack of in vivo delivery to the desired organ. Therefore, combining such agents with a nanocarrier is a potentially exciting next step for cell-based therapy. Finally, the arsenals of nanomaterials continue to expand. It is important that the nanostructures are characterized and designed carefully. For example, core–shell nanostructure confers higher gentamicin encapsulation, but incomplete release.
Related posts:
- Our findings correlate with the fact that intracellular upregulat
- In this context Bcl two, CDK, as well as other possible intracellular targets ca
- , 2008; De Baets et al, 2009) FAFLP is a high-resolution and re
- , 2009) However, B spartinae and three Harpophora isolates and
- Several scenarios can be envisioned that highlight the challenges